Thanks again, Mr. Chairman, for giving me the floor. I would like to ask our legislative clerk for clarification.
Mr. Garneau's goal was to only amend the definition of the term “pharmaceutical product” in order to make it consistent with those clauses that are amended by amendments LIB-4, LIB-5 and LIB-6, and specifically amendment LIB-5.
Once clause 2 has been completely deleted from Bill C-393, will the definition of “pharmaceutical product” still be adequate considering the amendments we have just passed?